In the days leading up to the CLSN massacre on 1/31/13, there were some serious hit pieces written by Adam Feuerstein of thestreetdotcom. The company's market cap was below $300 million which predicted failure for pIII oncology trials according to the Feuerstein-Ratian rule. We haven't seen any high profile hit pieces on INSM. The Motley Fool article seemed to be a fluff piece written by someone that knew little about INSM. Also, several weeks before pIII data, in a bold move, one investment bank (Aschoff at Brean Murray) covering CLSN lowered its price target from $7 to $1. We haven't seen any defections from the analysts covering INSM. They have been raising price targets, not lowering them. The only INSM detractors are on this MB...one a supposed surf dude, and the other, a KGB agent.